An observational study in Ventilator Acquired Pneumonia and Mechanical Ventilation Complication, sponsored by Region Skane. Recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Region Skane · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Ventilator-associated pneumonia (VAP) is a common and serious infection in patients receiving mechanical ventilation in intensive care units. Current diagnostic methods are imprecise, leading to unnecessary antibiotic use and delayed treatment. The ClusterVAP study aims to identify biologically and clinically distinct subgroups of patients with suspected VAP by analyzing proteins in bronchoalveolar lavage (BAL) fluid using advanced proteomic techniques. This multicentre observational study will enroll approximately 400 adult patients from intensive care units in Sweden, France, Portugal, Denmark, and the United Kingdom. BAL or mini-BAL samples collected for clinical reasons will be analyzed to define "pneumoclusters" and explore their association with patient outcomes. The study will also identify candidate biomarkers that could support future diagnostic tools. No experimental treatments are given; all patients receive standard care. Results may improve diagnostic accuracy and guide personalized treatment strategies for critically ill patients.
ClusterVAP is an exploratory, observational, prospective, multicentre cross-sectional study designed to identify biologically and clinically distinct subgroups ("pneumoclusters") among patients with suspected ventilator-associated pneumonia (VAP). The study will enroll approximately 400 adult patients admitted to intensive care units in Sweden, France, Portugal, Denmark, and the United Kingdom who are receiving mechanical ventilation and undergo bronchoalveolar lavage (BAL) or mini-BAL for clinical reasons.
Residual BAL supernatant will be processed for proteomic analysis using liquid chromatography tandem mass spectrometry (LC-MS/MS). Unsupervised consensus clustering will be applied to proteomic data, alone and in combination with clinical and microbiological variables, to define pneumoclusters. These clusters will be characterized by clinical features, microbiology, and radiology, and compared for 30-day outcomes including mortality, ventilator-free days, antibiotic-free days, ICU-free days, and hospital-free days. Differential protein abundance analysis will be used to identify candidate biomarkers for pragmatic cluster assignment.
Data will be collected in electronic case report forms hosted in REDCap, with built-in quality checks. All data will be pseudonymized, and biological samples will be stored under controlled conditions for up to ten years for confirmatory analyses. No experimental interventions are administered; all patients receive standard care. The study has been approved by the Swedish Ethical Review Authority (Dnr 2025-04564-01) and equivalent bodies in participating countries. Results will be disseminated through peer-reviewed publications and scientific conferences, with statistical code shared for transparency.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
This study's planned enrollment of 400 is above the median of 170 across 132 observational studies indexed under Pneumonia, Ventilator-Associated.
Browse Pneumonia, Ventilator-Associated studies →Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients (≥18 years) admitted to intensive care units in Sweden, France, Portugal, Denmark, and the United Kingdom who are receiving invasive mechanical ventilation and undergo bronchoalveolar lavage (BAL) or mini-BAL for clinical suspicion of lower respiratory tract infection. Patients are enrolled at the time of sampling and followed for 30-day outcomes. No experimental interventions are administered; all patients receive standard care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult patients (≥18 years) admitted to an intensive care unit (ICU). Receiving invasive mechanical ventilation. Undergoing bronchoalveolar lavage (BAL) or mini-BAL on clinical indication for suspected lower respiratory tract infection.
New or worsening clinical signs compatible with lower respiratory tract infection within the preceding 24 hours, defined as the treating clinician's suspicion plus at least one of:
Body temperature >38 °C or \<36 °C. Visually purulent tracheal secretions. Signs of reduced oxygenation (e.g., increased FiO₂ and/or decreased arterial pO₂, increased positive end-expiratory pressure or driving pressure).
Request for chest radiograph to investigate infection or new infiltrate. Initiation of antibiotic therapy targeting lower respiratory tract infection.
Exclusion Criteria:
BAL or mini-BAL performed solely for screening without suspicion of infection. Concurrent enrolment in the VAPmarkers study (reserved for external validation).
Age \<18 years. Any condition that, in the opinion of the investigator, would preclude safe participation or confound study objectives.
Adult ICU patients receiving mechanical ventilation who undergo bronchoalveolar lavage (BAL) or mini-BAL for clinical suspicion of lower respiratory tract infection. Residual BAL fluid will be analyzed using proteomic profiling to identify biological subgroups ("pneumoclusters"). No experimental intervention is administered; all patients receive standard care.
Distribution of patients into biologically distinct clusters ("pneumoclusters") based on BAL proteomic data
Unsupervised consensus clustering of bronchoalveolar lavage (BAL) proteomic profiles, alone and in combination with clinical and microbiological variables, will be performed to classify patients with suspected ventilator-associated pneumonia into biologically distinct clusters ("pneumoclusters"). The number of clusters, the number of patients per cluster, and key distinguishing features will be reported.
Time frame: Day 0 (at enrolment)
30-day all-cause mortality
Mortality status compared across identified clusters.
Time frame: 30 days after enrolment
Ventilator-free days
Number of days alive and free from invasive mechanical ventilation.
Time frame: 30 days after enrolment
Antibiotic-free days
Number of days alive and not receiving systemic antibiotics.
Time frame: 30 days after enrolment
ICU-free days
Number of days alive and not in an intensive care unit.
Time frame: 30 days after enrolment
Hospital-free days
Number of days alive and not hospitalized.
Time frame: 30 days after enrolment
Identification of candidate protein biomarkers for cluster assignment
Differential abundance analysis of bronchoalveolar lavage (BAL) proteomic data will be performed to identify candidate protein biomarkers that distinguish biologically defined patient clusters ("pneumoclusters"). The analysis will aim to derive a minimal set of proteins suitable for pragmatic cluster assignment in future cohorts. Results will include fold changes, statistical significance (e.g., adjusted p-values), and performance metrics (e.g., AUC) for each candidate biomarker.
Time frame: Day 0 (at enrolment)
Plan to share: Yes — De-identified individual participant data (IPD) underlying the published results will be made available upon reasonable request to the corresponding author, subject to approval by relevant ethics committees and execution of appropriate data transfer agreements. Statistical code will be shared alongside the main publication. No genetic data will be shared.
Supporting information: Study protocol, Analytic code
Time frame: De-identified individual participant data (IPD) and supporting documents will be available after publication of the main results and will remain available for up to 10 years after study completion or until the destruction of biological samples, whichever occurs first.
Access criteria: Access will be granted to qualified researchers affiliated with academic or healthcare institutions who submit a methodologically sound proposal. Requests should be directed to the corresponding author and will require approval by the study steering committee and relevant ethics committees.
Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.
Of 63 non-industry observational studies under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 19 months is close to that.
Counting every sponsor, half of 63 studies reached it within 20 months; a quarter within 12 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated →